Lineage Cell Therapeutics Inc
XBER:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
U
|
Uponor Oyj
LSE:0KI5
|
FI |
|
Robinhood Markets Inc
NASDAQ:HOOD
|
US |
|
V
|
Vicor Corp
XBER:VCV
|
US |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BT3 is 6.32 EUR with a low forecast of 3.41 EUR and a high forecast of 10.65 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
6.32
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 6.32 EUR with a low forecast of 3.41 EUR and a high forecast of 10.65 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 74%.
